Ursofalk^® (ursodeoxycholic acid, UDCA) is used for the treatment of Primary Biliary Cholangitis (PBC), for the dissolution of radiolucent gallstones and for hepatobiliary disorders associated with Cystic Fibrosis. UDCA helps stimulate impaired hepatobiliary secretion, protects the biliary epithelium against toxic effects of hydrophobic bile acids and protects hepatocytes from apoptosis.

Ursofalk^® is available in both solid and liquid oral formulations:

Ursofalk^® 500mg tablets Ursofalk^® 250mg capsules Ursofalk^® 250mg lemon flavoured suspension formulation to make swallowing easier.